Perifosine

Generic Name
Perifosine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H52NO4P
CAS Number
157716-52-4
Unique Ingredient Identifier
2GWV496552
Background

Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Indication

Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Phase 2
Completed
Conditions
Kidney Cancer
Interventions
Drug: Perifosine
First Posted Date
2007-07-11
Last Posted Date
2018-02-05
Lead Sponsor
AEterna Zentaris
Target Recruit Count
50
Registration Number
NCT00498966
Locations
🇺🇸

Investigative Site, Armonk, New York, United States

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

First Posted Date
2007-04-03
Last Posted Date
2018-02-22
Lead Sponsor
AEterna Zentaris
Target Recruit Count
40
Registration Number
NCT00455559

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

Phase 2
Completed
Conditions
Renal Cell Carcinoma
Interventions
Drug: Perifosine
First Posted Date
2007-03-19
Last Posted Date
2018-03-01
Lead Sponsor
AEterna Zentaris
Target Recruit Count
24
Registration Number
NCT00448721
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Investigative Site, Nashville, Tennessee, United States

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Perifosine
Drug: Docetaxel
First Posted Date
2007-02-05
Last Posted Date
2016-02-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT00431054
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 2
Completed
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Drug: Perifosine
First Posted Date
2007-01-17
Last Posted Date
2017-12-26
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
37
Registration Number
NCT00422656
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
First Posted Date
2006-12-22
Last Posted Date
2012-07-06
Lead Sponsor
AEterna Zentaris
Target Recruit Count
32
Registration Number
NCT00415064

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

First Posted Date
2006-11-20
Last Posted Date
2018-03-07
Lead Sponsor
AEterna Zentaris
Target Recruit Count
72
Registration Number
NCT00401388

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

First Posted Date
2006-11-17
Last Posted Date
2018-02-23
Lead Sponsor
AEterna Zentaris
Target Recruit Count
84
Registration Number
NCT00401011

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Perifosine
First Posted Date
2006-11-15
Last Posted Date
2018-02-22
Lead Sponsor
AEterna Zentaris
Target Recruit Count
121
Registration Number
NCT00399789
Locations
🇺🇸

AOI Pharmaceuticals Investigative Site, Tyler, Texas, United States

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

First Posted Date
2006-11-14
Last Posted Date
2018-03-14
Lead Sponsor
AEterna Zentaris
Target Recruit Count
381
Registration Number
NCT00398879
Locations
🇺🇸

AOI Pharmaceuticals Investigative Site, Appleton, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy